Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Icon Plc.

    Client Virtual Booth

    ICON PLC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    SERVICES

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Icon Plc
    Ireland Flag
    Country
    Country
    Ireland
    Address
    Address
    South County Business Park Leopardstown Dublin 18
    Telephone
    Telephone
    +353 (1) 291 2000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.iconplc.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/icon-plc-2
    Twitter
    Twitter
    https://twitter.com/ICONplc

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    BARDA Partners with ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial

    Details:

    The partnership aims to execute a Phase 2b clinical trial to assess the relative efficacy of a next generation COVID-19 vaccine compared to currently approved/authorised COVID-19 vaccines in the prevention of symptomatic, PCR confirmed SARS-CoV-2 infection.


    Lead Product(s): Undisclosed

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: Phase IIProduct Type: Vaccine

    Partner/Sponsor/Collaborator: BARDA

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership September 13, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    ICON Selected By BARDA To Conduct Anthrax Vaccine Clinical Trial

    Details:

    This clinical study will inform operational logistics and will not expose participants to anthrax. AV7909 is indicated for post-exposure prophylaxis of anthrax disease. Anthrax vaccine is also recommended for unvaccinated people of all ages who have been exposed to anthrax.


    Lead Product(s): AV7909

    Therapeutic Area: Infections and Infectious Diseases Product Name: AV7909

    Highest Development Status: Phase IIIProduct Type: Vaccine

    Partner/Sponsor/Collaborator: BARDA

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 06, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Evergreen Therapeutics Announces Agreement with ICON to Conduct Phase II Clinical Trial for COVID-19 Drug Candidate

    Details:

    The purpose of the study is to evaluate the efficacy of Evergreen’s EG-009A drug candidate for the treatment of moderate to severe COVID-19 cases.


    Lead Product(s): EG-009A

    Therapeutic Area: Infections and Infectious Diseases Product Name: EG-009A

    Highest Development Status: Phase IProduct Type: Undisclosed

    Partner/Sponsor/Collaborator: Evergreen Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement June 18, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    The 24-Month Follow-Up of DIAGNODE-2 With the Diabetes Vaccine Diamyd® Will be Presented in Early July

    Details:

    All 50 patients who participated in the extension of Diamyd Medical's Phase IIb trial DIAGNODE-2 with the diabetes vaccine Diamyd® have now made their 24-month visit, and data will be presented in early July.


    Lead Product(s): Recombinant human glutamic acid decarboxylase,Vitamin D

    Therapeutic Area: Endocrinology Product Name: Diamyd

    Highest Development Status: Phase IIProduct Type: Vaccine

    Recipient: Diamyd Medical AB

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 29, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search